Tag: GlobeNewswire

SUGAR LAND, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) — Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary inspection, heat-treating, and mechanical services, today announced that it will issue its third quarter 2026 earnings release on Wednesday, November 11, 2026, after the close of trading on the New York Stock Exchange. TEAM will host a conference call to discuss its financial and operational results on Thursday morning, November 12, 2026, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time).

Interested parties in the United States may participate toll-free by dialing (877) 270-2148. Interested parties internationally may dial (412) 902-6510. Participants should ask to join “TEAM, Inc. Third Quarter 2026 Conference Call.” This call will also be webcast on TEAM’s website at www.teaminc.com. An audio replay will be available on the Company’s website following the call.

The call will include a question-and-answer session, and investors are welcome to send questions to TISI@alpha-ir.com ahead of the scheduled call.

About Team, Inc.
Headquartered in Sugar Land, Texas, Team, Inc. (NYSE: TISI) is a global, leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary inspection, heat-treating, and mechanical services. We deploy conventional to highly specialized inspection, condition assessment, maintenance, and repair services that result in greater safety, reliability, and operational efficiency for our customers’ most critical assets. Through locations in 13 countries, we unite the delivery of technological innovation with over a century of progressive, yet proven integrity and reliability management expertise to fuel a better tomorrow. For more information, please visit www.teaminc.com.

Contact:
Alpha Advisory Group
Nick Teves or Joseph Caminiti
TISI@alpha-ir.com

• Two Invited Presentations Showcase Clinical Progress in Solid Tumors and Allogene’s Broader Vision in Oncology and Autoimmune Disease
• Preclinical Poster Features Next-Generation DLL3/CD70 Dual CAR T Product Candidate for Small Cell Lung Cancer and Other Neuroendocrine Tumors, Demonstrating Continued Innovation with Dagger^® Technology

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced its participation in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Phoenix, Arizona. The Company’s participation includes two invited presentations and a preclinical poster showcasing the breadth and continued evolution of its platform.

“Our presence at SITC underscores the promise of our off-the-shelf CAR T platform, from clinical progress in solid tumors to next-generation innovation informed by learnings across our pipeline,” said Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics. “We are building on this experience to develop a new generation of cell therapies with the potential to expand patient access, reach more treatment settings and transform care across oncology and autoimmune disease.”

Scientific Presentation: Advancing a First-in-Class Allogeneic CAR T Approach in Renal Cell Carcinoma: Clinical Experience from the TRAVERSE Study
Thursday, November 5, 2026
9:05-9:15 a.m. MT
Jeffrey McLeroy, M.D.
Session I: Cell Therapies and Technologies
Sheraton, 2nd Level – Valley of the Sun Ballroom

Scientific Presentation: Allogeneic CAR T: A Platform Built for Patient Access – in Cancer and Beyond
Friday, November 6, 2026
4:25-4:40 p.m. MT
Zachary Roberts, M.D., Ph.D.
Biotech Session 107b: Next Generation of Off the Shelf I/O
Phoenix Convention Center, North Building, 300 Level, Halls BC

Complementing these presentations, the Company will present preclinical data evaluating a novel off-the-shelf DLL3/CD70 dual CAR T product candidate for small cell lung cancer and other neuroendocrine tumors. The findings suggest that careful selection of the genomic location for site-specific-integration of the CAR can improve CAR T cell performance in controlling tumors. Confirming and extending observations presented earlier this year with BCMA, the data show pairing the DLL3 CAR with a CAR targeting CD70 can enhance resistance to immune-mediated rejection, illustrating that Dagger^® technology can be coupled with other CARs. These findings reinforce the potential of the Dagger technology as a versatile foundation for Allogene’s next-generation pipeline, supporting the development of off-the-shelf CAR T therapies across additional targets for both hematological and solid tumors as well as autoimmune disease.

Poster: Off-the-shelf DLL3/CD70 dual CAR T cells with optimized site-specific integration for SCLC and neuroendocrine tumors
Friday, November 6, 2026
Abstract #207
12:15-1:45 p.m. MT and 5:30-7:00 p.m. MT
Presenter: Zhe Li, Ph.D.
Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4-5

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to the early stage of development of Allogene’s next-generation product candidates; the possibility that preclinical findings, including those relating to the DLL3/CD70 dual CAR T product candidate and Dagger technology, may not translate into clinical results; uncertainties regarding the safety, efficacy and ability of Allogene’s product candidates to achieve meaningful clinical benefit; challenges in developing and applying novel CAR T technologies across different targets, indications and patient populations; and uncertainties regarding the timing, cost and success of clinical development and regulatory approval of Allogene’s product candidates. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Dagger^® is a trademark of Allogene Therapeutics, Inc.

Allogene’s investigational AlloCAR T oncology products utilize Cellectis technologies. Cemacabtagene ansegedleucel (cema-cel) was developed based on an exclusive license granted by Cellectis to Servier. Servier has granted Allogene exclusive rights to cema-cel in the U.S., all EU Member States and the United Kingdom. The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T program. ALLO-329 (CD19/CD70) in autoimmune disease uses CRISPR gene-editing technology. 

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

Leslie Bryant
Executive Director, Corporate Communications
Leslie.Bryant@allogene.com

Global integration gives advertisers access to native, real-time AU reporting across web and CTV, plus automated attention-threshold optimization

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) — Teads (NASDAQ: TEAD), the omnichannel outcomes platform, today announced the expansion of its partnership with Adelaide, the leader in attention-based media quality measurement. The integration brings Adelaide’s AU metric, which predicts a placement’s likelihood of capturing attention and driving outcomes, directly into Teads Ad Manager (TAM), enabling advertisers to measure, analyze, and optimize campaigns for media quality in real time across both web and CTV InStream formats.

Through this platform integration, advertisers can activate Adelaide measurement with a single click and view real-time AU data alongside standard delivery metrics such as viewability, video views, and click-through rates. Reporting includes detailed breakdowns by ad format, device, and placement. Additionally, Teads’ Attention Threshold optimization feature can be used to set an AU floor, automatically filtering out low-attention inventory to improve campaign efficiency and performance.

“Our priority is to give advertisers frictionless access to the industry’s leading media quality metrics directly within our platform,” said Neala Brown, Global Head of Data, Measurement, and Insights at Teads. “By natively embedding Adelaide’s AU metrics and automated optimization capabilities into Teads Ad Manager, we are empowering our clients to eliminate media waste and maximize campaign effectiveness across web and CTV inventory at scale.”

“To move the industry forward, media quality measurement must be both accessible and actionable,” said Marc Guldimann, CEO and Co-founder of Adelaide. “This partnership gives Teads advertisers the ability to evaluate media quality in real time and automatically optimize toward higher-AU inventory. By bringing an outcome-trained quality signal directly into optimization, we’re helping brands invest in inventory that is more likely to deliver meaningful business results.”

Key benefits for advertisers include:

• A richer view of media quality and attention potential, with granular, real-time visibility into how campaigns perform across both web and CTV InStream formats, broken down by format, device, and placement.
• More accountable media decisions, with Adelaide AU reported alongside standard metrics like viewability, video views, and CTR directly within Teads Ad Manager (TAM) to help eliminate media waste and connect exposure with quality.
• A stronger foundation for quality-based optimization, allowing advertisers to activate automated Attention Threshold optimization to set an AU floor, filter out low-attention inventory, and prioritize placements that are more likely to drive full-funnel business outcomes.

Availability

Adelaide AU measurement is available globally in Teads Ad Manager (TAM).

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. You can generally identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “guidance,” “outlook,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “foresee,” “potential” or “continue” or the negative of these terms or other similar expressions that concern our expectations, strategy, plans or intentions.

We have based these forward-looking statements largely on our current expectations and projections regarding future events and trends that we believe may affect our business, financial condition and results of operations. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors, including but not limited to: the risk that our integration with Adelaide may not yield the anticipated commercial benefits, advertiser adoption, or campaign performance optimizations as expected; technical and operational challenges related to maintaining real-time AU reporting across web and CTV formats; the highly competitive nature of the digital, CTV, and streaming advertising markets; and the other important risks described in the section entitled “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed for the year ended December 31, 2025, and our Quarterly Reports on Form 10-Q filed for the quarters ended March 31, 2026, and June 30, 2026, filed with the Securities and Exchange Commission (the “SEC”), which are available on our website at https://investors.teads.com/ and on the SEC’s website at www.sec.gov.

Accordingly, you should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those projected in the forward-looking statements. We undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About Adelaide
Adelaide is the leader in attention-based media quality measurement. Our mission is to bring increased transparency and fairness to advertising by supplying the market with a precise, omnichannel media quality metric connected to business outcomes. Adweek has called Adelaide’s AU “the attention economy’s most widely recognized metric.” Proven to predict full-funnel outcomes more accurately than any existing metric, AU helps the world’s largest brands make smarter investment decisions, activate attention data programmatically, and drive better performance. Adelaide is named after the global epicenter of evidence-based marketing in southern Australia and headquartered in New York City. For more information, visit adelaidemetrics.com.

About Teads
Teads Holding Co. (“Teads”) (Nasdaq: TEAD) is a leading omnichannel advertising platform focused on driving outcomes for brand and performance advertisers across screens. With a focus on meaningful business outcomes for full funnel objectives, Teads drives value by leveraging predictive AI technology to connect quality media, beautiful brand creative, and context-driven addressability and measurement. Teads is directly partnered with more than 10,000 publishers and 20,000 advertisers globally. The company is headquartered in New York, New York, with a global team of around 1,700 people in 30+ countries.

For more information, visit www.teads.com.

Media Contact
press@teads.com

Investor Relations Contact
IR@teads.com
(332) 205-8999

Funding provided through the Bank’s Community Development Partnership Program

ISELIN, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) — Provident Bank, a leading New Jersey-based financial institution, announced today that it has awarded $83,000 in grants to ten local non-profit organizations through its Community Development Partnership Program. The grants will advance financial literacy education, affordable housing, homeownership, and help meet the credit needs of the communities served.

The Community Development Partnership Program builds on Provident Bank’s long record of working alongside non-profits to strengthen the communities it serves and foster lasting economic prosperity.

Combined, the recipients of these major grants received a total of $83,000. The local non-profit organizations include:

• Central Jersey Housing Resource Center: Supports households facing challenges by helping them find safe, affordable housing that meets their needs.
• Clinton Hill Community Action: Partners with residents to revitalize the Clinton Hill neighborhood and ensure that development is equitable and just.
• Habitat for Humanity of Greater Newark: Builds affordable housing for families with low to moderate incomes through new construction, home rehabilitation, and neighborhood revitalization.
• Housing & Community Development Network of New Jersey: Dedicated to advancing economic justice, empowering low-income communities, and fostering inclusive participation in public policy.
• Housing Partnership: Creates lasting and responsible homeownership through education and financial coaching.
• Ironbound Community Corporation: Engages and empowers individuals, families, and groups to achieve their aspirations and collaboratively build a community.
• New Jersey Community Capital: Creating communities through strategic investments and knowledge.
• NORWESCAP: Strengthens communities by creating opportunities that improve the lives of low-income individuals and families.
• Urban League of Essex County: Empowering African Americans and disadvantaged residents to achieve social and economic self-sufficiency through programs in education, employment, housing, and economic development that transform lives and communities.
• Urban League of Union County: Assists the community in achieving social and economic equality by providing resources and support services.

“This year we’re able to support more organizations with a larger investment, and that reflects how much need and opportunity there is across our communities,” said Roxanne Camejo, Senior Vice President, Community Development Officer, Provident Bank. “These partners are delivering real results in housing, education and financial empowerment, and we’re proud to stand alongside them.”

Since July 2023, Provident Bank has partnered with more than a dozen local non-profit organizations through the Community Development Partnership Program, all sharing a common goal of fostering economic opportunity and sustainable community growth.

Through the Community Development Partnership Program, Provident Bank continues to invest in organizations that help New Jersey residents buy homes, build financial skills, and access new opportunities, laying the groundwork for stronger, more inclusive communities.

About Provident Bank

Founded in Jersey City in 1839, Provident Bank is the oldest community-focused financial institution based in New Jersey and is the wholly owned subsidiary of Provident Financial Services, Inc. (NYSE:PFS). With assets of $25.85 billion as of September 30, 2026, Provident Bank offers a wide range of customized financial solutions for businesses and consumers with an exceptional customer experience delivered through its convenient network of 135 branches across New Jersey and parts of New York and Pennsylvania, via mobile and online banking, and from its customer contact center. The bank also provides fiduciary and wealth management services through its wholly owned subsidiary, Beacon Trust Company, and insurance services through its wholly owned subsidiary, Provident Protection Plus, Inc. To learn more about Provident Bank, go to www.provident.bank or call our customer contact center at 800.448.7768.

Media Contacts:
Provident Bank
Keith Buscio, Director Public Relations & Communications
Keith.Buscio@provident.bank

Vested
Providentbank@fullyvested.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4d8d2f14-9deb-4bb7-bb79-3a6266609450

Transactions during 27 October 2026 – 02 November 2026
On 7 May 2026, Alm. Brand A/S announced a share buy-back program of up to DKK 593 million, as described in company announcement no. 23/2026.

The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.

The following transactions were made under the share buy-back program 27 October – 02 November 2026:

	Number of shares bought	Average purchase price	Amount (DKK)
Accumulated, last announcement 27 October 2026 28 October 2026 29 October 2026 30 October 2026 02 November 2026	19,576,795 120,000  303,000  275,000  80,000  132,997	16.57 17.68 17.74 17.22 17.20 17.31	324,350,861 2,121,684 5,376,129 4,736,050 1,375,600 2,302,125
Total, 27 October – 02 November 2026	910,997	17.47	15,911,588
Accumulated under the program	20,487,792	16.61	340,262,449

With the transactions stated above Alm. Brand A/S holds a total of 53,224,462 own shares, corresponding to 3.79% of the total number of outstanding shares.

Contact
Please direct any questions regarding this announcement to:

Investors and equity analysts:                                 

VP, Head of Investor Relations & ESG                    
Mads Thinggaard                                                       
Mobile no, +45 2025 5469                                      

Attachments

• Alm Brand_Share buyback 27 October – 02 November 2026
• AS 60 2026 – Transactions under share buyback program

MONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) — Milestone^® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report its financial results for the third quarter ended September 30, 2026, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30 am ET.

To access the live conference call, participants may register here.

Conference Details:
Conference Date:	Friday, November 13, 2026
Conference Time:	8:30 am ET
Conference Dial-in:	1-877-407-0792
International Dial-in:	1-201-689-8263
Conference ID:	13763324

Participants can use Guest dial-in #s above and be answered by an operator OR click the Call Me™ link for instant telephone access to the event. The Call me™ link will be made active 15 minutes prior to scheduled start time.

A replay of the audio webcast of the call will be available under the News & Events section of Milestone’s website, www.milestonepharma.com.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST^® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib.
https://milestonepharma.com/.

Contact:

Investor Relations

Kevin Gardner, kgardner@lifesciadvisors.com

Media Relations 

Rebecca Novak, rnovak@milestonepharma.com

SHENYANG, China, Nov. 03, 2026 (GLOBE NEWSWIRE) — Geely Auto Group unveiled its latest methanol hybrid powertrain technology and launched the Geely Xingyao 6 EF, the world’s first production methanol hybrid passenger vehicle. The launch of the new technology marked a significant milestone in Geely’s nearly two-decade commitment to methanol as a viable, scalable, green alternative fuel for the automotive industry.

The Geely Xingyao 6 EF is a flexible-fuel hybrid sedan capable of running on methanol, gasoline, or electricity, with the distinct capability to utilize methanol and gasoline in any mix ratio within the same fuel tank. This uniquely flexible power utilization capability addresses critical shortcomings of electric vehicles in cold climates while offering a pragmatic bridge to the adoption of green mobility.

Breaking the Cold-Climate Barrier

At the heart of this innovative new powertrain technology is Geely’s methanol hybrid engine, which achieves a thermal efficiency of 48.15%, the highest among mass-produced methanol engines globally. The engine incorporates 350-bar high-pressure direct injection and a high-power ignition system, enabling reliable cold starts at temperatures approaching minus 40℃. This capability directly addresses the severe range degradation that electric vehicles experience in northern China’s winter conditions.

The vehicle is also equipped with a methanol concentration sensor that analyzes the fuel mixture in real time through subtle electrical current changes as fuel passes through the sensor. The engine control unit then adjusts injection and ignition parameters accordingly, ensuring stable and efficient operation regardless of the methanol-to-gasoline ratio.

Performance and Efficiency

Under CLTC standards, the Geely Xingyao 6 EF offers 230 kilometers of electric range for daily urban commuting. The vehicle’s combined range with a full methanol tank and charged battery reaches approximately 1,250 km, while a full tank of gasoline and charged battery extends that range to 1,880 km.

The sedan is built on Geely’s GEA global intelligent electric architecture, featuring a 4.8-meter body length and a 2,756-millimeter wheelbase. It comes equipped with the Flyme Auto intelligent cockpit system, a comprehensive safety package, and a body structure with 71.6% high-strength steel.

Pragmatic Solutions to a Sustainable Future

Geely Auto Group’s commitment to methanol technologies is positioned within a broader multi-energy approach to sustainable mobility that includes electric, hybrid, and hydrogen technologies. The company has invested in methanol research and development since 2005 and built a complete value chain spanning methanol production, storage, transportation, refuelling infrastructure, and vehicle applications.

Development of methanol technologies also provides an advantage to Geely Auto Group in providing solutions to utilize sustainable green alcohol fuels including methanol and ethanol used in markets around the world. To further advance the market adaption of green methanol, Geely Auto Group has also developed the world’s first carbon exhaust capture system for automobiles which can facilitate the recycling of waste carbon into green methanol forming a carbon net zero closed cycle.

Geely positions the Xingyao 6 not as a replacement for electric or conventional hybrid models, but as a complementary solution that fills a critical gap in cold-climate and long-distance sustainable green mobility.

About Geely Auto Group

Geely Auto Group is a leading global automotive company headquartered in Hangzhou, China. Part of Zhejiang Geely Holding Group, Geely Auto Group develops and manufactures passenger vehicles under the Geely, Lynk & Co, and Zeekr brands.

With a strong focus on technology innovation, electrification, and sustainable mobility, Geely Auto Group operates world-class R&D centers and manufacturing facilities across China, Europe, and key international markets. The Group is committed to delivering safe, high-quality, and intelligent vehicles enabled by advanced technologies such as hybrid powertrains, full-electric architectures, smart connectivity, and autonomous driving systems.

As a global company, Geely Auto Group continues to expand its international presence through strategic partnerships, localized operations, and industry-leading platforms. Geely strives to create mobility solutions that are greener, smarter, and more accessible, driving forward the future of sustainable transportation.

Media Contact
Contact Person: Janet Chen
Email: media@geely.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6a28e03c-9817-437f-bdee-e5b054024715

To Nasdaq Copenhagen

Terms for Nykredit’s and Totalkredit’s auctions

The total bond offering in connection with the interest rate adjustment of adjustable-rate mortgages (ARMs) and the refinancing of floating-rate loans at Nykredit’s and Totalkredit’s refinancing auctions amounts to approx. DKK 42.8bn. The auctions will be conducted in the period from 16th to 20th November 2026.

In the auction period, Nykredit Realkredit A/S will publish the amounts offered in the individual ISINs daily at nykredit.com/ir.

Terms for the auctions including a list of the bonds offered, amounts offered and an auction schedule appear from Appendices 1, 2 and 3.

Questions regarding the bond sale as well as technical matters may be addressed to Nykredit Realkredit A/S, Group Treasury, Christian Mauritzen, tel +45 44 55 10 14.

Other questions may be addressed to Corporate Communications, tel +45 44 55 14 50.

Appendix 1: Auction terms

Bonds offered, amounts offered and auction schedule
Appendix 2 and 3 contains auction schedules, lists of bonds offered, expected amounts and settlement dates.

Every morning at 09:00 CET in the auction period, the amounts offered on that particular day in the individual ISINs will be published at nykredit.com/ir under “Debt”, where you can find information on the refinancing auctions.

Refinancing principles – ARMs
The Nykredit Group offers fixed-rate non-callable bullet covered bonds for interest rate adjustment of ARMs based on the “refinancing price” principle.

For interest rate adjustment at the refinancing price, the bonds are sold at one or more bond auctions. The price is fixed as a weighted average of the prices obtained at the auctions.

If the Nykredit Group finds that the amount of bonds offered at an auction is not sufficient to obtain a market-consistent price, the refinancing price will instead be based on the Consolidated Reference Price of the bond in question quoted on Nasdaq Copenhagen.

Refinancing principles – floating-rate loans
Floating-rate loans are refinanced at one stand-alone auction.

• ISIN DK000955566-6 is non-callable.
  The mortgage bond is offered and settled at a price of 100.20.
  Based on the offer price, bids must be made in terms of the reference rate spread used for the regular coupon fixing.

Reference Rate: Cita/6 months
Fixing method: Fourth last Business Day (adjusted)
Expiring ISIN: DK000954209-4 and DK0009954373-8

Credit ratings
All auctioned bonds issued through Capital Centre H are rated AAA by S&P.
All auctioned bonds issued through Capital Centre J are government-guaranteed and therefore not
rated.

Bids
Bids for fixed-rate non-callable bullet covered bonds must be made in terms of amount and price. With respect to bonds maturing within 14 months, bids must be made in prices correct to three decimals. Other bids must be made correct to two decimals.

For all DKK-denominated bonds bids must be made in multiples of DKK 100,000, and for all EUR-denominated bonds in multiples of EUR 10,000.

More than one bid may be made in the same ISIN.

Type of auction
Mortgage bonds issued through Capital Centre H will be auctioned through Nasdaq Copenhagen’s auction submarket CPH Auctions. Participants are stockbrokers and investors with access to the auction submarket at Nasdaq Copenhagen.

Bonds issued through Capital Centre J will be auctioned through Bloomberg’s auction system AUPD.
Market participants who do not already have access to this system should contact Nykredit Realkredit
A/S, Group Treasury, prior to the auctions.

Allotment
As regards bonds for which bids are made in terms of price, bids above the cut-off price will be settled in full, and bids at the cut-off price may be accepted on a pro rata basis.

With respect to bonds for which bids are made in terms of reference rate spread, bids below the cut-off spread will be settled in full, and bids at the cut-off spread may be accepted on a pro rata basis.

All trades concluded will be published through Nasdaq Copenhagen.

Allotment at the auctions will take place as soon as possible, but not later than 10 minutes after closing.

Conditional offering of bonds with interest rate trigger
A condition of the final completion of a sale (allotment) of bonds offered with an interest rate trigger is that the yield-to-maturity of the bonds will not rise by more than 5 percentage points. Reference is made to the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act.

Value date
All bonds at auction will be subject to long settlement. The value date of all trades executed at the auctions will be 4th January 2027.

Reverse facility
As the bonds traded will be subject to long settlement, Nykredit Realkredit A/S offers a reverse facility to auction participants whose bids have been accepted and who require the bonds after only two trading days.

By means of the reverse facility, Nykredit Realkredit A/S offers to sell the allotted bonds subject to the conventional two settlement days and subsequently repurchase them with 4th January 2027 as the value date.

The size of the reverse facility will be determined on an individual basis but cannot exceed the amount allotted to each individual bidder. The reverse facility can be made conditional on the investor providing a corresponding amount of bonds maturing on 1st January 2027.

Reverse facilities will be arranged on an individual basis. Please contact Nykredit Realkredit A/S, Group Treasury, Morten Willendrup, tel +45 44 55 16 92.

Reservations regarding auctions
If, contrary to expectations, technical problems should prevent Nykredit Realkredit A/S from conducting an auction through Nasdaq Copenhagen’s auction submarket, a stock exchange announcement will be issued containing the practical details of the auction.

Tap sales
Tap sales are made on 17th and 18th November 2026. Bids may be made on these days by contacting Nykredit Realkredit A/S, Group Treasury.

Other terms
The Nykredit Group is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. If a sale of bonds has to be cancelled, the market will be notified immediately by a stock exchange announcement.

Appendix 2: Settlement times and amounts offered for bonds issued through Capital Centre H.

ISIN

Capital centre

IT / RF*

Coupon

Maturity date

Bids on

Interest rate trigger

LCR level

Currency

Auction dates

Settlement

Offering (million)

Start

End

Cut-off

Allotment

DK0009515363

SDO (H)

RF

1

01-01-2028

Price

–

1b

DKK

Tapsale**

400

DK0009519357

SDO (H)

RF

1

01-01-2029

Price

–

1b

DKK

16-11-2026

10:30

10:40

900

DK0009524001

SDO (H)

RF

1

01-01-2030

Price

–

1b

DKK

17-11-2026

19-11-2026

10:30

10:40

10,800

DK0009529075

SDO (H)

RF

1

01-01-2031

Price

–

1b

DKK

16-11-2026

11:30

11:40

600

DK0009533267

SDO (H)

RF

1

01-01-2032

Price

–

1b

DKK

17-11-2026

19-11-2026

11:30

11:40

10,500

DK0009541286

SDO (H)

RF

1

01-01-2034

Price

–

non-level

DKK

Tapsale**

100

DK0009555237

SDO (H)

IT / RF*

1

01-04-2028

Price

–

1b

DKK

17-11-2026

19-11-2026

13:00

13:10

4,600

DK0009555070

SDO (H)

IT / RF*

1

01-01-2028

Price

7,40%

non-level

EUR

16-11-2026

13:00

13:10

70

DK0009546673

SDO (H)

RF

3

01-01-2030

Price

–

non-level

EUR

Tapsale**

16

DK0009555666

SDO (H)

RF

Adjustable

01-07-2030

Yield

–

1b

DKK

20-11-2026

10:30

10:40

13,900

* (IT) Interest rate and refinancing trigger / (RF) Refinancing trigger
** Tap sales are conducted on 17th and 18th November 2026.

Please note that the Nykredit Group is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. The market must be notified hereof immediately by way of a company announcement.

Appendix 3: Settlement times and amounts offered for bonds issued through Capital Centre J (Care Homes)

ISIN

Capital centre

IT / RF*

Coupon

Maturity Date

Bids on

LCR Level

Currency

Auction dates

Settlement

Offering (million)

Start

End

Cut-off

Allotment

DK0009518466

SDO (J)

RF

1

01-01-2028

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009518540

SDO (J)

RF

1

01-01-2029

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009523896

SDO (J)

RF

1

01-01-2030

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009529158

SDO (J)

RF

1

01-01-2031

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009533184

SDO (J)

RF

1

01-01-2032

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009537847

SDO (J)

RF

1

01-01-2033

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009542763

SDO (J)

RF

1

01-01-2034

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009546830

SDO (J)

RF

1

01-01-2035

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009550519

SDO (J)

RF

1

01-01-2036

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009555153

SDO (J)

RF

1

01-01-2037

Price

1a

DKK

16-11-2026

11:00

11:10

242

* (IT) Interest rate and refinancing trigger / (RF) Refinancing trigger

Please note that the Nykredit Group is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. The market must be notified hereof immediately by way of a company announcement.

Attachment

• Terms for Nykredit and Totalkredits auctions

To Nasdaq Copenhagen

Terms for Nykredit’s and Totalkredit’s auctions

The total bond offering in connection with the interest rate adjustment of adjustable-rate mortgages (ARMs) and the refinancing of floating-rate loans at Nykredit’s and Totalkredit’s refinancing auctions amounts to approx. DKK 42.8bn. The auctions will be conducted in the period from 16th to 20th November 2026.

In the auction period, Nykredit Realkredit A/S will publish the amounts offered in the individual ISINs daily at nykredit.com/ir.

Terms for the auctions including a list of the bonds offered, amounts offered and an auction schedule appear from Appendices 1, 2 and 3.

Questions regarding the bond sale as well as technical matters may be addressed to Nykredit Realkredit A/S, Group Treasury, Christian Mauritzen, tel +45 44 55 10 14.

Other questions may be addressed to Corporate Communications, tel +45 44 55 14 50.

Appendix 1: Auction terms

Bonds offered, amounts offered and auction schedule
Appendix 2 and 3 contains auction schedules, lists of bonds offered, expected amounts and settlement dates.

Every morning at 09:00 CET in the auction period, the amounts offered on that particular day in the individual ISINs will be published at nykredit.com/ir under “Debt”, where you can find information on the refinancing auctions.

Refinancing principles – ARMs
The Nykredit Group offers fixed-rate non-callable bullet covered bonds for interest rate adjustment of ARMs based on the “refinancing price” principle.

For interest rate adjustment at the refinancing price, the bonds are sold at one or more bond auctions. The price is fixed as a weighted average of the prices obtained at the auctions.

If the Nykredit Group finds that the amount of bonds offered at an auction is not sufficient to obtain a market-consistent price, the refinancing price will instead be based on the Consolidated Reference Price of the bond in question quoted on Nasdaq Copenhagen.

Refinancing principles – floating-rate loans
Floating-rate loans are refinanced at one stand-alone auction.

• ISIN DK000955566-6 is non-callable.
  The mortgage bond is offered and settled at a price of 100.20.
  Based on the offer price, bids must be made in terms of the reference rate spread used for the regular coupon fixing.

Reference Rate: Cita/6 months
Fixing method: Fourth last Business Day (adjusted)
Expiring ISIN: DK000954209-4 and DK0009954373-8

Credit ratings
All auctioned bonds issued through Capital Centre H are rated AAA by S&P.
All auctioned bonds issued through Capital Centre J are government-guaranteed and therefore not
rated.

Bids
Bids for fixed-rate non-callable bullet covered bonds must be made in terms of amount and price. With respect to bonds maturing within 14 months, bids must be made in prices correct to three decimals. Other bids must be made correct to two decimals.

For all DKK-denominated bonds bids must be made in multiples of DKK 100,000, and for all EUR-denominated bonds in multiples of EUR 10,000.

More than one bid may be made in the same ISIN.

Type of auction
Mortgage bonds issued through Capital Centre H will be auctioned through Nasdaq Copenhagen’s auction submarket CPH Auctions. Participants are stockbrokers and investors with access to the auction submarket at Nasdaq Copenhagen.

Bonds issued through Capital Centre J will be auctioned through Bloomberg’s auction system AUPD.
Market participants who do not already have access to this system should contact Nykredit Realkredit
A/S, Group Treasury, prior to the auctions.

Allotment
As regards bonds for which bids are made in terms of price, bids above the cut-off price will be settled in full, and bids at the cut-off price may be accepted on a pro rata basis.

With respect to bonds for which bids are made in terms of reference rate spread, bids below the cut-off spread will be settled in full, and bids at the cut-off spread may be accepted on a pro rata basis.

All trades concluded will be published through Nasdaq Copenhagen.

Allotment at the auctions will take place as soon as possible, but not later than 10 minutes after closing.

Conditional offering of bonds with interest rate trigger
A condition of the final completion of a sale (allotment) of bonds offered with an interest rate trigger is that the yield-to-maturity of the bonds will not rise by more than 5 percentage points. Reference is made to the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act.

Value date
All bonds at auction will be subject to long settlement. The value date of all trades executed at the auctions will be 4th January 2027.

Reverse facility
As the bonds traded will be subject to long settlement, Nykredit Realkredit A/S offers a reverse facility to auction participants whose bids have been accepted and who require the bonds after only two trading days.

By means of the reverse facility, Nykredit Realkredit A/S offers to sell the allotted bonds subject to the conventional two settlement days and subsequently repurchase them with 4th January 2027 as the value date.

The size of the reverse facility will be determined on an individual basis but cannot exceed the amount allotted to each individual bidder. The reverse facility can be made conditional on the investor providing a corresponding amount of bonds maturing on 1st January 2027.

Reverse facilities will be arranged on an individual basis. Please contact Nykredit Realkredit A/S, Group Treasury, Morten Willendrup, tel +45 44 55 16 92.

Reservations regarding auctions
If, contrary to expectations, technical problems should prevent Nykredit Realkredit A/S from conducting an auction through Nasdaq Copenhagen’s auction submarket, a stock exchange announcement will be issued containing the practical details of the auction.

Tap sales
Tap sales are made on 17th and 18th November 2026. Bids may be made on these days by contacting Nykredit Realkredit A/S, Group Treasury.

Other terms
The Nykredit Group is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. If a sale of bonds has to be cancelled, the market will be notified immediately by a stock exchange announcement.

Appendix 2: Settlement times and amounts offered for bonds issued through Capital Centre H.

ISIN

Capital centre

IT / RF*

Coupon

Maturity date

Bids on

Interest rate trigger

LCR level

Currency

Auction dates

Settlement

Offering (million)

Start

End

Cut-off

Allotment

DK0009515363

SDO (H)

RF

1

01-01-2028

Price

–

1b

DKK

Tapsale**

400

DK0009519357

SDO (H)

RF

1

01-01-2029

Price

–

1b

DKK

16-11-2026

10:30

10:40

900

DK0009524001

SDO (H)

RF

1

01-01-2030

Price

–

1b

DKK

17-11-2026

19-11-2026

10:30

10:40

10,800

DK0009529075

SDO (H)

RF

1

01-01-2031

Price

–

1b

DKK

16-11-2026

11:30

11:40

600

DK0009533267

SDO (H)

RF

1

01-01-2032

Price

–

1b

DKK

17-11-2026

19-11-2026

11:30

11:40

10,500

DK0009541286

SDO (H)

RF

1

01-01-2034

Price

–

non-level

DKK

Tapsale**

100

DK0009555237

SDO (H)

IT / RF*

1

01-04-2028

Price

–

1b

DKK

17-11-2026

19-11-2026

13:00

13:10

4,600

DK0009555070

SDO (H)

IT / RF*

1

01-01-2028

Price

7,40%

non-level

EUR

16-11-2026

13:00

13:10

70

DK0009546673

SDO (H)

RF

3

01-01-2030

Price

–

non-level

EUR

Tapsale**

16

DK0009555666

SDO (H)

RF

Adjustable

01-07-2030

Yield

–

1b

DKK

20-11-2026

10:30

10:40

13,900

* (IT) Interest rate and refinancing trigger / (RF) Refinancing trigger
** Tap sales are conducted on 17th and 18th November 2026.

Please note that the Nykredit Group is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. The market must be notified hereof immediately by way of a company announcement.

Appendix 3: Settlement times and amounts offered for bonds issued through Capital Centre J (Care Homes)

ISIN

Capital centre

IT / RF*

Coupon

Maturity Date

Bids on

LCR Level

Currency

Auction dates

Settlement

Offering (million)

Start

End

Cut-off

Allotment

DK0009518466

SDO (J)

RF

1

01-01-2028

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009518540

SDO (J)

RF

1

01-01-2029

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009523896

SDO (J)

RF

1

01-01-2030

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009529158

SDO (J)

RF

1

01-01-2031

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009533184

SDO (J)

RF

1

01-01-2032

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009537847

SDO (J)

RF

1

01-01-2033

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009542763

SDO (J)

RF

1

01-01-2034

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009546830

SDO (J)

RF

1

01-01-2035

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009550519

SDO (J)

RF

1

01-01-2036

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009555153

SDO (J)

RF

1

01-01-2037

Price

1a

DKK

16-11-2026

11:00

11:10

242

* (IT) Interest rate and refinancing trigger / (RF) Refinancing trigger

Please note that the Nykredit Group is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. The market must be notified hereof immediately by way of a company announcement.

Attachment

• Terms for Nykredit and Totalkredits auctions

• Study demonstrates feasibility of saline-based hybrid IVUS-OCT imaging without iodinated contrast during image acquisition
• FDA-cleared OCTIV system now in commercial clinical use, with patient cases ongoing

TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company developing imaging technologies to guide cardiovascular procedures, today announced the presentation of data from its OCTIV™ hybrid IVUS–OCT imaging system at Transcatheter Cardiovascular Therapeutics (“TCT”) 2026. The study, conducted in an animal model before OCTIV’s use in patients, demonstrated the feasibility of using saline instead of iodinated contrast during image acquisition. The FDA-cleared system is now in commercial clinical use, with its first U.S. placement completed and patient cases ongoing. The findings were presented by Megha Prasad, MD, MS, in an abstract titled “Saline-Based Hybrid IVUS-OCT Imaging: Feasibility of Contrast-Free Dual-Modality Intracoronary Imaging in a Porcine Model.”

“These findings highlight the potential of OCTIV to provide complementary ultrasound and optical images using saline, eliminating the need for iodinated contrast during image acquisition,” said Thomas Looby, President and Chief Executive Officer of Conavi Medical. “Since this study was conducted, OCTIV has advanced into commercial clinical use, with our first U.S. placement completed and patient cases ongoing. We are pleased to share these results as we build clinical experience with the system.”

Study Results

The prospective feasibility study evaluated hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging of major coronary arteries in three swine, using saline as the sole OCT flushing medium. Investigators performed 26 imaging pullbacks in native vessels and following stent placement, assessing feasibility, safety, catheter performance and image quality.

Key findings included:

• Interpretable images across all 26 pullbacks: Hybrid imaging was successfully performed in all targeted vessels without iodinated contrast during image acquisition.
• Complementary vessel assessment: OCT provided high-resolution visualization of luminal morphology and stent architecture, while IVUS enabled assessment of vessel dimensions and deeper wall structures within the same pullback.
• Continuous IVUS imaging: IVUS assessment remained available independently of blood clearance, with high-resolution OCT visualization achieved when saline flushing was adequate.
• No observed device-related complications: No device-related complications, coronary injury, sustained arrhythmia or procedural mortality occurred.
• Potential to eliminate iodinated contrast during image acquisition: The findings support further clinical evaluation of saline-based hybrid imaging, which could be particularly relevant for patients at risk of contrast-associated acute kidney injury.  

About Conavi Medical
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented OCTIV hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration. For more information, visit http://www.conavi.com/.

Forward-Looking Statements
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the anticipated clinical benefits and performance of OCTIV, continued clinical use, placements at additional U.S. institutions, participation in TCT 2026, the commercialization and commercial launch of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging and the ability of Conavi’s hybrid imaging system to meet market needs. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact
Mark Quick, Chief Financial Officer | 416-483-0100
Christina Cameron, Investor Relations | 416-483-0100 ext. 121 | IR@conavi.com
Susan Thomas, Media | 619-540-9195